<DOC>
	<DOCNO>NCT00447434</DOCNO>
	<brief_summary>Nattokinase potent fibrinolytic enzyme extract Natto . The objective study compare efficacy natto extract take healthy volunteer , dialysis patient , patient cardiovascularrisk factor fibrinolytic factor blood lipid . The study two primary objective : evaluate effect oral intake nattokinase normal subject , patient dialysis , patient cardiovascular high risk group , compare effect oral intake nattokinase among three group . Fifteen subject , 20-70 year , group enrol take capsule natto extract orally 2 month . Fibrinolytic factor , vital sign blood lipid efficacy , body weight , renal function self-administered questionnaire safety assess screening , 3 , 7 , 28 , 56 day initiation intake , 2 week cease intake .</brief_summary>
	<brief_title>Efficacy Safety Natto Extract</brief_title>
	<detailed_description>This study employ open-label , parallel-group design . Adult men woman meet inclusion/exclusion criterion give write consent participate assign one three group accord condition : Group A- normal volunteer ; Group B- patient dialysis ; Group C- patient cardiovascular high risk group . Each group enroll 15 subject . After two four week run-in period , subject give nattokinase orally 8 week , ask stop take nattokinase 2 week evaluate effect long-term intake cease intake nattokinase . Laboratory test , include fibrinogen , T-PA , PAI-1 , D-dimer , total cholesterol , LDL-C , HDL-C , TG , vital sign body weight evaluated screening visit , 3 day , 1 week , 4 week , 8 week , 10 week ( 2 week cease intake ) visit . Patient self-evaluation tolerance physical improvement assess Patient Questionnaire 3-day , 1- , 4- , 8- , 10-week visit . Each patient carefully monitor development adverse event ( AE ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>In order enrol study , potential study subject must meet follow inclusion criterion : 1 . Men nonpregnant woman least 20 young 70 year age . 2 . Subjects , opinion Investigator , able comply requirement study . 3 . Subjects adequately informed nature risk study give write informed consent prior receive investigational product . Groupspecific inclusion criterion : Group A : 1 . Subjects risk factor cardiovascular disease ( see Group C ) chronic renal disease history . 2 . Male subject Creatinine≦1.4 mg/dl ; Female≦1.3 mg/dl . Group B : 1 . Patients receive dialysis institute least 3 month . Group C : 1 . Patients coronary artery disease ( CAD ) ; OR 2 . Patients peripheral arterial occlusive disease ( PAOD ) ; OR 3 . Patients history stroke ; OR 4 . Patients history transient ischemic attack ( TIA ) ; OR 5 . Patients history pulmonary embolism ( PE ) ; OR 6 . Patients history deep vein thrombosis ( DVP ) ; OR 7 . Patients 2 major risk factor cardiovascular disease ( CVD ) list National Health Insurance guideline hypertension , smoking , diabetes mellitus ( DM ) , atrial fibrillation ( AF ) , lipid disorder , overweight , physical inactivity , etc . In order enrol study , potential study patient must follow exclusion criterion : 1 . Known allergy component study product . 2 . Current use warfarin . 3 . Patients active disease status . 4 . Patients acute disease , opinion investigator , suitable participate study . Groupspecific exclusion criterion : Group A : 1 . Patients coronary artery disease ( CAD ) . 2 . Patients peripheral arterial occlusive disease ( PAOD ) . 3 . Patients history stroke . 4 . Patients history transient ischemic attack ( TIA ) . 5 . Patients history pulmonary embolism ( PE ) . 6 . Patients history deep vein thrombosis ( DVP ) . 7 . Patients 2 major risk factor cardiovascular disease ( CVD ) list National Health Insurance guideline hypertension , smoking , diabetes mellitus ( DM ) , atrial fibrillation ( AF ) , lipid disorder , overweight , physical inactivity , etc . 8 . Patients history chronic renal disease . 9 . Male subject Creatinine＞1.4 mg/dl ; Female＞1.3 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Nattokinase</keyword>
	<keyword>fibrinolytic factor</keyword>
	<keyword>blood lipid</keyword>
	<keyword>nutrimental supplement</keyword>
</DOC>